WORK_OF_ART – Talk Bio

Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease

1 month ago talkbio0Tagged AI-driven, Anemia, CDE, China, Chronic Kidney Diseases, Clearance, clinical-stage biotech, Drug Discovery, Generative AI, Indonesian language, Insilico Medicine, ISM4808, License Agreement, Oral cavity, Ph.D., Pharma, PHD inhibitor, TaiGen Biotechnology

Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

3 months ago talkbio0Tagged adjuvant treatment, atezolizumab, ctDNA-guided therapy, Disease-Free Survival, ESMO, genentech, IMvigor011, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Roche (company), Signatera, Tecentriq

Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche

FDA Pushes Back Agios’ Pyrukynd Thalassemia Decision to December

4 months ago talkbio0Tagged Agios, decision delay, Liver damage, PDUFA, Pyrukynd, REMS, Thalassemia, United States Food and Drug Administration

FDA; Agios; Pyrukynd; thalassemia; PDUFA; decision delay; REMS; hepatocellular injury

FDA Extends PDUFA Date for Regenxbio’s Hunter Syndrome Gene Therapy RGX-121

5 months ago talkbio0Tagged clemidsogene lanparvovec, Deferred, gene therapy, IDS gene, Infrequent, Mucopolysaccharidosis II, PDUFA, Regenxbio, RGX-121, United States Food and Drug Administration

FDA delay; PDUFA extension; Regenxbio; Hunter syndrome; clemidsogene lanparvovec; RGX-121; gene therapy; Mucopolysaccharidosis II; IDS gene; rare disease